Join Our Network
Pharmacy / Merchant
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023
Everest Pharmaceuticals Ltd. · Capsule
/ Piece
The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.
Hydroxyurea is indicated for the treatment of:
Polycythaemia vera
Essential thrombocythemia
Sickle cell anemia
Resistant chronic myeloid leukemia
Locally advanced squamous cell carcinomas of the head and neck in combination with chemoradiation.
Hydroxyurea is converted to a free radical nitroxide (NO) in vivo, and transported by diffusion into cells where it quenches the tyrosyl free radical at the active site of the M2 protein subunit of ribonucleotide reductase, inactivating the enzyme. The entire replicase complex, including ribonucleotide reductase, is inactivated and DNA synthesis is selectively inhibited, producing cell death in S phase and synchronization of the fraction of cells that survive. Repair of DNA damaged by chemicals or irradiation is also inhibited by hydroxyurea, offering potential synergy between hydroxyurea and radiation or alkylating agents. Hydroxyurea also increases the level of fetal hemoglobin, leading to a reduction in the incidence of vasoocclusive crises in sickle cell anemia. Levels of fetal hemoglobin increase in response to activation of soluble guanylyl cyclase (sGC) by hydroxyurea-derived NO.
Polycythaemia Vera: Administer 15-20 mg/kg orally once daily.Essential Thrombocythemia: Administer 15 mg/kg orally once daily.Solid Tumors- Intermittent Therapy: Administer 80 mg/kg orally every three days. Continuous Therapy: Administer 20-30 mg/kg orally once daily (qDay)Head & Neck Tumors: Start 80 mg/kg orally every three days (q3days) seven days before initiating irradiation.Chronic Myelocytic Leukemia, Resistant: Administer 20-40 mg/kg orally once daily.Sickle Cell Disease: Initiate at 15 mg/kg/day as a single dose; monitor blood cell counts every two weeks. Titrate by 5 mg/kg/day every 12 weeks, but do not exceed 35 mg/kg/day.
Hydroxyurea can enhance toxicity when used alongside antiretroviral drugs and may also interfere with laboratory tests measuring uric acid, urea, or lactic acid levels.
Fever
Feeling very tired
Chills
Shortness of breath
Body aches
Bleeding or unexplained bruising
Pregnancy category D. There are no adequate and well-controlled studies in pregnant women. There are potential risk to fetus and women should avoid becoming pregnant while being treated with hydroxyurea. It is excreted in human milk. Because of the potential for serious adverse reactions in a breastfed infant from hydroxyurea, including carcinogenicity, patients should be discontinue breastfeeding during treatment with hydroxyurea.
Myelosuppression: Hydroxyurea causes severe myelosuppression. Treatment with hydroxyurea should not be initiated if bone marrow function is markedly depressed. Bone marrow suppression may occur, and leukopenia is generally its first and most common manifestation. Some patients, treated at the recommended initial dose of 15 mg/kg/day, have experienced severe or life-threatening myelosuppression.Malignancies: Hydroxyurea is a human carcinogen. In patients receiving long-term hydroxyurea for myeloproliferative disorders, secondary leukemia has been reported. Skin cancer has also been reported in patients receiving long-term hydroxyurea. Advise protection from sun exposure and monitor for the development of secondary malignancies.Embryo-Fetal Toxicity: Based on the mechanism of action and findings in animals, Hydroxyurea can cause fetal harm when administered to a pregnant woman.
Hydroxyurea can cause fetal harm based on findings from animal studies and the drug’s mechanism of action. There are no data with hydroxyurea use in pregnant women to inform a drug-associated risk. Hydroxyurea is excreted in human milk. Because of the potential for serious adverse reactions in a breastfed infant from hydroxyurea, including carcinogenicity, discontinue breastfeeding during treatment with hydroxyurea.
Cytotoxic Chemotherapy
Store at or below 25°C, in a cool and dry place. Keep away from light. Keep out of the reach of children.